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ABSTRACT
The appropriate target for BP in patients with CKD and hypertension remains uncertain. We report prespeciﬁed subgroup analyses of outcomes in participants with baseline CKD in the Systolic Blood Pressure
Intervention Trial. We randomly assigned participants to a systolic BP target of ,120 mm Hg (intensive
group; n=1330) or ,140 mm Hg (standard group; n=1316). After a median follow-up of 3.3 years, the
primary composite cardiovascular outcome occurred in 112 intensive group and 131 standard group CKD
participants (hazard ratio [HR], 0.81; 95% conﬁdence interval [95% CI], 0.63 to 1.05). The intensive group
also had a lower rate of all-cause death (HR, 0.72; 95% CI, 0.53 to 0.99). Treatment effects did not differ
between participants with and without CKD (P values for interactions $0.30). The prespeciﬁed main kidney
outcome, deﬁned as the composite of $50% decrease in eGFR from baseline or ESRD, occurred in 15
intensive group and 16 standard group participants (HR, 0.90; 95% CI, 0.44 to 1.83). After the initial 6
months, the intensive group had a slightly higher rate of change in eGFR (20.47 versus 20.32 ml/min per
1.73 m2 per year; P,0.03). The overall rate of serious adverse events did not differ between treatment
groups, although some speciﬁc adverse events occurred more often in the intensive group. Thus, among
patients with CKD and hypertension without diabetes, targeting an SBP,120 mm Hg compared with ,140
mm Hg reduced rates of major cardiovascular events and all-cause death without evidence of effect
modiﬁcations by CKD or deleterious effect on the main kidney outcome.
J Am Soc Nephrol 28: 2812–2823, 2017. doi: https://doi.org/10.1681/ASN.2017020148

Hypertension is common in patients with CKD, and
it is a well established risk factor for cardiovascular
disease (CVD) and progression of CKD.1–3 There
is, however, uncertainty about the optimal BP
target for preventing CVD and slowing decline in
kidney function in these patients, in part related to
lack of evidence derived from randomized trials.
Previous randomized trials comparing intensive
and standard BP lowering in patients with CKD
without diabetes showed no overall beneﬁt of
intensive BP treatment on their primary kidney
outcomes.4,5 Observational studies and small- or
moderate-sized clinical trials that have included
2812
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patients with mild to moderate CKD have yielded
mixed results, with some suggesting a direct linear
relationship between BP and CVD, whereas others
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suggest a “J-shape” relationship, depending on the speciﬁc BP
parameter and type of CVD studied.6–8
The Systolic Blood Pressure Intervention Trial (SPRINT)
was designed to compare the effects of intensive BP lowering
(systolic BP [SBP] ,120 mm Hg) and standard BP control

CLINICAL RESEARCH

(SBP,140 mm Hg) on clinical outcomes.9 It is the largest
randomized trial to date to assess the effect of different BP
targets on CVD and kidney outcomes in patients with CKD.
Overall, intensive SBP lowering resulted in lower rates of the
primary CVD composite outcome and all-cause death; the

Table 1. Baseline characteristics of the SPRINT participants with CKD
Characteristics
Age, mean6SD, yr
Age $75 yr, no. (%)
Women, no. (%)
Race or ethnicity, no. (%)
Non-Hispanic black
Hispanic
Non-Hispanic white
Other
Serum creatinine, mg/dl
All
Age $75 yr
Age ,75 yr
eGFR, mean (SD), ml/min per 1.73 m2a
All
Age $75 yr
Age ,75 yr
Urinary ACR
Mean (SD), mg/gb
Median (interquartile range)
BP, mean6SD, mm Hg
SBP
DBP
Distribution of SBP, mm Hg
#132
.132 to ,145
$145
Antihypertensive medications, no. per participant 6SD
Participants not using antihypertensive medications, no. (%)
Statin use, no. (%)
Aspirin use, no. (%)
Smoking status
Never smoker, no. (%)
Former smoker, no. (%)
Current smoker, no. (%)
Missing data, no.
CVD
Clinical, no. (%)
Subclinical, no. (%)
Framingham score, mean6SD, %
Framingham score $15%, no. (%)
Body mass index, mean6SDc
Fasting plasma total cholesterol, mean6SD, mg/dl
Fasting plasma LDL cholesterol, mean6SD, mg/dl
Fasting plasma total triglycerides, mean6SD, mg/dl
Fasting plasma glucose, mean6SD, mg/dl

Intensive Treatment, n=1330 Standard Treatment, n=1316

Total, n=2646

72.069.0
584 (43.9)
537 (40.4)

71.969.5
577 (43.8)
521 (39.6)

71.969.3
1161 (43.9)
1058 (40.0)

325 (24.4)
94 (7.1)
885 (66.5)
26 (2.0)

312 (23.7)
96 (7.3)
893 (67.9)
15 (1.1)

637 (24.1)
190 (7.2)
1778 (67.2)
41 (1.6)

1.43 (0.39)
1.41 (0.38)
1.46 (0.41)

1.43 (0.38)
1.39 (0.31)
1.47 (0.42)

1.43 (0.39)
1.40 (0.34)
1.46 (0.41)

47.9 (9.5)
47.4 (9.5)
48.2 (9.4)

47.9 (9.5)
47.3 (9.0)
48.3 (9.9)

47.9 (9.5)
47.4 (9.2)
48.2 (9.7)

80.9 (236.2)
12.8 (6.5–42.6)

80.3 (250.5)
13.8 (6.1–43.5)

80.6 (243.4)
13.3 (6.4–43.1)

139.1616.1
75.1612.2

139.2616.0
74.8612.2

139.2616.1
74.9612.2

463 (34.8)
425 (32.0)
442 (33.2)
2.0961.01
61 (4.6)
657 (49.7)
754 (56.7)

468 (35.6)
412 (31.3)
436 (33.1)
2.1161.01
62 (4.7)
697 (53.4)
728 (55.5)

931 (35.2)
837 (31.6)
878 (33.2)
2.1061.01
123 (4.7)
1354 (51.5)
1482 (56.1)

606 (45.6)
617 (46.4)
107 (8.1)
0

601 (45.7)
600 (45.6)
114 (8.7)
1

1207 (45.6)
1217 (46.0)
221 (8.4)
1

263 (19.8)
121 (9.1)
27.1614.3
1042 (78.4)
29.565.8
186.6640.7
108.9635.0
124.9669.4
98.2613.9

257 (19.5)
121 (9.2)
27.2624.3
1027 (78.2)
29.465.7
184.9640.6
106.0633.5
133.6689.0
98.3612.4

520 (19.7)
242 (9.2)
27.1614.3
2069 (78.3)
29.465.8
185.8640.7
107.4634.3
129.2679.9
98.2613.1

To convert LDL and total cholesterol to millimoles per liter, multiply by 0.0259. To convert triglycerides to millimoles per liter, multiply by 0.0113, and to convert
glucose to millimoles per liter, multiply by 0.0555.
a
On the basis of the four-variable MDRD equation.
b
For urinary ACR: n=1284 in the intensive treatment group and n=1270 in the standard treatment group.
c
Calculated as weight in kilograms divided by height in meters squared.
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treatment effect was not modiﬁed by the presence or absence
of CKD at baseline. Moreover, there was no difference in incidence of the main composite kidney outcome deﬁned as
$50% reduction in eGFR from baseline or ESRD. The objective of this report is to further characterize CVD and kidney
outcomes in the SPRINT participants with CKD at baseline.
RESULTS
Baseline Characteristics and Study Retention in the
CKD Subgroup

Of the total SPRINT cohort (n=9361), 2646 participants
(28.3%) had CKD at baseline and constitute the focus of
this report (Supplemental Figure 1). Baseline demographic,
clinical, and laboratory characteristics were not signiﬁcantly
different between the randomized groups (Table 1). Mean age
of the participants with CKD was 71.969.3 years old, and
43.9% of them were 75 years old or older. Forty percent
were women. Most (67.2%) of the participants were non-Hispanic whites, but blacks and Hispanics were well represented.
Participants were taking a mean of 2.161.0 antihypertensive
medications at trial entry and had a mean baseline SBP/diastolic BP (DBP) of 139.2616.1/74.9612.2 mm Hg.
The SBP intervention in the SPRINT was terminated early
because of proven efﬁcacy as previously described.10 The median follow-up duration was 3.3 (25th–75th percentile, 2.8–
3.8) years. A total of 135 participants in the intensive group

and 162 participants in the standard group discontinued their
respective assigned SBP intervention, withdrew their consent,
or were lost to follow-up (Supplemental Figure 1). However,
all participants were included in the analyses.
Use of Antihypertensive Agents during Follow-Up

The mean number of antihypertensive medications prescribed
at the study visit immediately before termination of the BP
intervention was 2.961.2 in the intensive group compared
with 2.061.2 in the standard group (Table 2). The use of almost all types of antihypertensive medications was higher in
the intensive group than in the standard group.
Achieved BP during Follow-Up

SBP decreased rapidly during the ﬁrst month in both treatment
groups (Figure 1). Thereafter, SBP remained relatively stable in the
standard group but continued to decline for several months in
the intensive group before stabilizing. At 1 year of follow-up, the
model-based estimated mean (6SEM) SBP/DBP was 123.36
0.4/66.960.3 mm Hg in the intensive group and 136.96
0.4/73.860.3 mm Hg in the standard group. Over the duration
of follow-up, the SBP/DBP was 123.060.2/66.360.2 mm Hg in
the intensive group and 135.360.2/72.460.2 mm Hg in the standard group, with an average SBP difference of 12.3 mm Hg.
Cardiovascular Outcomes and All-Cause Mortality

There was no signiﬁcant effect modiﬁcation by CKD status
when considering the intensity of SBP lowering on the primary

Table 2. Use of antihypertensive medications during follow-up in the SPRINT participants with CKD
Medication Usage

Intensive Treatment, n=1330

Standard Treatment, n=1316

No. of medications
Mean no. of medications (SD)
Zero medications, no. (%)
One medication, no. (%)
Two medications, no. (%)
Three medications, no. (%)
Four or more medications, no. (%)
RAS blockers, no. (%)
Angiotensin-converting enzyme inhibitor
Angiotensin receptor blocker
Direct renin inhibitor
Diuretics, no. (%)
Thiazide type
Loop diuretics
Aldosterone receptor antagonists
Other potassium-sparing diuretics
a-1 Blockers, no. (%)
Central a-2 agonists or other central-acting drugs, no. (%)
Calcium channel blockers, no. (%)
Dihydropyridines
Nondihydropyridines
Direct vasodilators, no. (%)
b-Blockers, no. (%)

2.90 (1.24)
25 (1.9)
124 (9.3)
376 (28.3)
398 (29.9)
407 (30.6)
953 (71.7)
471 (35.4)
482 (36.2)
0
895 (67.3)
622 (46.8)
249 (18.7)
113 (8.5)
38 (2.9)
172 (12.9)
51 (3.8)
810 (60.9)
753 (56.6)
64 (4.8)
153 (11.5)
694 (52.2)

2.02 (1.23)
123 (9.3)
359 (27.3)
399 (30.3)
278 (21.1)
157 (11.9)
750 (57.0)
396 (30.1)
355 (27.0)
0
613 (46.6)
396 (30.1)
200 (15.2)
60 (4.6)
39 (3.0)
88 (6.7)
22 (1.7)
491 (37.3)
428 (32.5)
66 (5.0)
55 (4.2)
555 (42.2)

Listed are the mean numbers of medications taken by participants as well as the numbers of participants taking various numbers of medications and speciﬁc
medication classes at the study visit immediately before termination of the SBP intervention. RAS, renin-angiotensin system.
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Figure 1. Separation in achieved BP levels between the two intervention groups in the SPRINT participants with CKD. The broken line
and open circles denote the intensive group; the solid line and closed circles denote the standard group. Vertical bars show 95% CIs for
the mean at each time point.

CVD outcome or all-cause death (P values for interaction:
P=0.30 and P=0.95, respectively).
Among participants with CKD at baseline, rates of the primary CVD outcome were 112 of 1330 (2.68% per year) versus
131 of 1316 (3.19% per year) in the intensive and standard
groups, respectively (hazard ratio [HR], 0.81; 95% conﬁdence
interval [95% CI], 0.63 to 1.05) (Figure 2A). The corresponding rates of all-cause death were 70 of 1330 (1.61% per year)
and 95 of 1316 (2.21% per year), respectively (HR, 0.72; 95%
CI, 0.53 to 0.99) (Figure 2B). The effect of intensive SBP lowering on the individual components of the primary composite
(CVD) outcome was not signiﬁcantly different between the
two treatment groups (Table 3).
Effects of intensive BP lowering on the primary CVD outcome and all-cause death, alone and in combination, in subgroups deﬁned by age, sex, race, eGFR, and albuminuria
categories are presented in Supplemental Tables 1–3. In participants with CKD and age $75 years old at baseline, the
relative HRs of the primary CVD outcome (HR, 0.64; 95%
CI, 0.45 to 0.92), all-cause death (HR, 0.64; 95% CI, 0.43 to
0.96), and the composite of primary CVD outcome or allcause death (HR, 0.66; 95% CI, 0.49 to 0.90) were lower in
the intensive group compared with the standard group.
J Am Soc Nephrol 28: 2812–2823, 2017

Furthermore, the statistical interactions unadjusted for multiple comparisons between age and the effects of intensive SBP
lowering on the primary CVD outcome (Supplemental Table
1) and the composite of primary CVD outcome and all-cause
death (Supplemental Table 3) were marginally statistically
signiﬁcant, suggesting a more pronounced beneﬁt of SBP lowering in older individuals.
Kidney Outcomes

The main kidney outcome, deﬁned as a conﬁrmed decrease
in eGFR of $50% or development of ESRD, occurred in 15
participants (1.1%) in the intensive group and 16 participants
(1.2%) in the standard group (HR, 0.90; 95% CI, 0.44 to 1.83)
(Figure 2C). These ﬁndings were consistent with the observations in subgroups deﬁned by age, sex, race, eGFR, or albuminuria, although the numbers of events in these subgroups
were too small to allow for meaningful interpretations (data
not shown).
There was no difference in the incidence of a conﬁrmed
decrease in eGFR of $50% from baseline between the intensive group and the standard group (0.8% versus 0.9%; P=0.58)
(Table 4). We also explored alternative thresholds of eGFR
decline as outcomes.11 Although there were no differences
Intensive BP Control in CKD
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Figure 2. Kaplan-Meier curves for pre-speciﬁed outcomes in SPRINT participants with CKD. Panel A shows the primary cardiovascular
outcome, deﬁned as the composite of myocardial infarction, acute coronary syndrome, stroke, acute decompensated heart failure, and
death from cardiovascular causes. Panel B shows the all-cause death outcome. Panel C shows the main kidney outcome, deﬁned as the
composite of a decrease in eGFR of $50% from baseline (conﬁrmed by repeat testing $90 days later) or the development of ESRD. The
broken lines depict the intensive group; the solid lines depict the standard group.

in the incidence of a conﬁrmed decline in eGFR of $40%
between the two randomized groups, participants in the intensive group were more likely to experience a conﬁrmed
2816
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$30% decline in eGFR than participants in the standard
group (6.9% versus 3.3%; HR, 2.03; 95% CI, 1.42 to 2.91).
To assess the possibility that the higher risk of $30% decline in
J Am Soc Nephrol 28: 2812–2823, 2017
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Table 3. Cardiovascular and mortality events in the SPRINT participants with CKD
Outcome
Primarya outcome
Myocardial infarction
Acute coronary syndrome
Stroke
Heart failure
CVD death
All-cause death
Primary outcome or all-cause death
Primary outcome or
cardiovascular procedure

Intensive
Treatment, n=1330

Standard
Treatment, n=1316

Intensive Treatment
Versus Standard Treatment

No. of events

Percent per 1 yr

No. of events

Percent per 1 yr

HR (95% CI)

P Value

112
44
15
27
41
18
70
152
127

2.68
1.03
0.35
0.63
0.96
0.41
1.61
3.62
3.06

131
45
11
27
52
30
95
179
161

3.19
1.07
0.26
0.64
1.24
0.70
2.21
4.35
3.98

0.81 (0.63 to 1.05)
0.94 (0.62 to 1.44)
1.35 (0.60 to 3.08)
0.99 (0.57 to 1.70)
0.72 (0.47 to 1.10)
0.57 (0.31 to 1.02)
0.72 (0.53 to 0.99)
0.82 (0.66 to 1.02)
0.81 (0.63 to 1.05)

0.12
0.79
0.47
0.96
0.13
0.06
0.04
0.08
0.12

a
The sum of the individual components of the primary composite outcome is greater than the number of primary composite outcome events, because some
participants experienced more than one component event.

eGFR in the intensive group was primarily due to an acute
effect of the intervention, we examined the kidney function
using only eGFR determined after the 6-month follow-up
visit. These analyses showed no differences in the incidence
of $30%, $40%, or $50% decline in eGFR between the intensive and standard groups (Table 5). The rates of change in
eGFR using the values at 6 months after randomization as
baseline were 20.47 ml/min per 1.73 m2 per year in the intensive group and 20.32 ml/min per 1.73 m2 per year in the
standard group (P,0.03) (Figure 3).
There was no signiﬁcant difference in incident albuminuria
between the intensive group (3.56%) and the standard group
(4.72%; HR, 0.73; 95% CI, 0.50 to 1.05); this ﬁnding was
consistent among the predeﬁned subgroups (data not shown).
Urinary albumin-to-creatinine ratio (ACR) level was, however,
consistently lower in the intensive group than in the standard
group (P,0.001 for all time points before 48 months; P,0.01
at 48 months) (Figure 4).
Serious Adverse Events and Clinical Alerts in the
CKD Subgroup

There was no difference in overall serious adverse events (SAEs)
and adverse events associated with hypotension, syncope, bradycardia, injurious falls, hyponatremia, hypernatremia, or orthostatic hypotension between the two treatment groups.
There were, however, increased risks for hypokalemia (HR,
1.87; 95% CI, 1.02 to 3.43), hyperkalemia (HR, 1.36; 95%
CI, 1.01 to 1.82), and ARF (HR, 1.46; 95% CI, 1.10 to 1.95)
in the intensive group compared with in the standard group.
The numbers of these adverse events expressed as annual rates
are presented in Table 6, whereas the absolute numbers of
these occurring during the entire follow-up period are presented in Supplemental Table 4.
Numbers Needed to Treat for Beneﬁts and Harm

Estimated numbers needed to treat to prevent a primary composite outcome event, death from any cause, and death from
cardiovascular causes in the CKD subgroup at 4 years of the
J Am Soc Nephrol 28: 2812–2823, 2017

follow-up were 66, 28, and 61, respectively. The numbers
needed to harm for ARF, hypokalemia, and hyperkalemia
events were 35, 131, and 41, respectively (Supplemental
Table 5).
DISCUSSION

Intensive reduction in SBP resulted in a substantial decrease in
the primary CVD outcome and all-cause death without evidence of effect modiﬁcations by baseline CKD status. There was
also no difference in the main kidney outcome between the two
randomized groups in the participants with CKD at baseline.
Intensive SBP lowering also resulted in a slightly higher rate of
eGFR decline and higher rates of hypokalemia, hyperkalemia,
and ARF.
Previous randomized trials comparing different levels of
BP targets in patients with CKD were not sufﬁciently powered
to assess the effects on CVD or mortality outcomes.4,5,12 Two
recent randomized trials have examined the cardiovascular
beneﬁts of lower SBP targets similar to those in the SPRINT.
Neither the Secondary Prevention of Small Subcortical Strokes
Trial13 nor the Action to Control Cardiovascular Risk in Diabetes Trial14 found signiﬁcant differences in the primary
CVD outcome between the lower and standard BP targets.
Of note, the mean baseline eGFR of both study cohorts was
.80 ml/min per 1.73 m2, and outcomes speciﬁcally in the
CKD subgroup have not been reported. In contrast,
the SPRINT targeted recruitment of persons with CKD and
therefore, provides a better opportunity to understand the
cardiovascular effects of a lower SBP in adults with CKD
and hypertension.
The effects of BP lowering on CVD and mortality are the
most important contributions of the SPRINT to the CKD
literature. The lack of signiﬁcant statistical interaction between
the SBP treatment effect and CKD status implies that the beneﬁts observed in the entire SPRINT cohort also applied to the
CKD subgroup. This lack of statistical interaction is perhaps
Intensive BP Control in CKD
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Table 4. Incidence of various levels of decline in eGFR from baseline values in the SPRINT participants with CKD
eGFR Reduction
from Baseline, %a
50
40
30

No. of Events (% per 1 yr)b

Intensive Treatment Versus Standard Treatment

Intensive Treatment, n=1330

Standard Treatment, n=1316

HR (95% CI)

P Value

10 (0.25)
30 (0.74)
92 (2.33)

12 (0.31)
19 (0.49)
44 (1.15)

0.79 (0.34 to 1.83)
1.51 (0.85 to 2.68)
2.03 (1.42 to 2.91)

0.58
0.16
,0.01

a
Each patient with eGFR decline from the baseline value to a level below the designated threshold (30%, 40%, or 50%) was conﬁrmed by a second laboratory test
at least 90 d later. The patients with $40% decline in eGFR include all patients with $30% decline, whereas patients with $50% decline included all patients
with $40% decline and $30% decline.
b
Number of ﬁrst occurrence of these events (eGFR decline to a level below the designated threshold conﬁrmed at least 90 d later) during the entire follow-up period;
percentage per person-year that experienced the event is in parentheses.

not surprising given that the large majority (66%) of the participants had a baseline eGFR $45 ml/min per 1.73 m2, a relatively low median baseline albuminuria (12.8 mg/g), and a
slow chronic eGFR decline during follow-up (,0.5 ml/min
per 1.73 m2 per year), suggesting that the CKD participants in
the SPRINT generally had relatively mild CKD and maintained their kidney function during the trial. Intensive SBP
lowering resulted in a signiﬁcant reduction in all-cause death
in the CKD subgroup; the effect size was, in fact, very similar
to that in the entire cohort10 (28% and 27%, respectively).
Therefore, our ﬁndings present the best available evidence to
date in favor of intensive SBP reduction as a means to improve
survival in patients with CKD and hypertension who are
plagued with very high mortality rate.
Results of the CVD outcomes and all-cause death were generally consistent within the CKD subgroup across other clinical
characteristics. It is of particular interest that lower SBP seemed
to reduce the risks for the primary CVD outcome in those with
CKD who were $75 years old at baseline, consistent with
experience in participants who were $75 years old in the entire SPRINT cohort.15
The effects of BP lowering on kidney disease progression are
also of great importance for the CKD population. The two
largest clinical trials that have addressed this issue in patients
with CKD without diabetes, the Modiﬁcation of Diet in Renal
Disease (MDRD) Study4 and the African American Study of
Kidney Disease and Hypertension (AASK),5 showed no overall
beneﬁt of intensive BP treatment on their primary kidney
outcomes. Post hoc analyses of both studies, however,

suggested a beneﬁt of intensive BP treatment in the subgroup
with signiﬁcant proteinuria.4,16 Clinical trial meta-analyses
yielded conﬂicting results regarding the potential effect of
BP reduction on development of ESRD.17,18
There was no beneﬁt of intensive SBP lowering on a variety
of kidney outcomes in the SPRINT participants with baseline
CKD; however, there was also no adverse effect on the main
kidney composite outcome. The SPRINT population differed
from those in previous clinical trials in the CKD population.
Patients with proteinuria .1 g/d were excluded from participation. The SPRINT enrolled a racially diverse population;
participants in the MDRD Study were predominantly whites,
whereas participation in the AASK was restricted to blacks.
Neither the MDRD Study nor the AASK targeted an SBP as
low as 120 mm Hg. Despite these differences, the SPRINT
results with regard to kidney outcomes in patients with
CKD are consistent with the main results of the MDRD Study
and the AASK. Therefore, the totality of the data from randomized trials to date does not provide evidence of a beneﬁcial
effect of intensive BP lowering on the progression of kidney
disease in patients without signiﬁcant proteinuria, and it also
does not provide evidence of substantial harm.
An acute decrease in GFR after BP lowering has been described in previous trials4,5 and is thought to be caused by
hemodynamic changes in the renal microcirculation. In the
SPRINT, there was an acute decline in eGFR in the intensive
group after randomization. In contrast, there was a slight increase in eGFR in the standard group during the ﬁrst 6
months. It is likely that the higher rate of $30% decline in

Table 5. Incidence of various levels of decline in eGFR from values at 6 months postrandomization in the SPRINT participants
with CKD
eGFR Reduction
from Month 6, %a
50
40
30

No. of Events (% per 1 yr)b

Intensive Treatment Versus Standard Treatment

Intensive Treatment, n=1330

Standard Treatment, n=1316

HR (95% CI)

P Value

7 (0.17)
15 (0.37)
44 (1.09)

4 (0.10)
14 (0.36)
35 (0.91)

1.65 (0.48 to 5.62)
1.01 (0.49 to 2.10)
1.19 (0.76 to 1.85)

0.42
0.98
0.44

a
Each patient with eGFR decline from the 6-mo value to a level below the designated threshold (30%, 40%, or 50%) was conﬁrmed by a second laboratory test at
least 90 d later. The patients with $40% decline in eGFR include all patients with $30% decline, whereas patients with $50% decline included all patients with
$40% decline and $30% decline.
b
Number of ﬁrst occurrence of these events (eGFR decline to a level below the designated threshold conﬁrmed at least 90 d later) during the entire follow-up period
after 6 months postrandomization; percentage per person-year that experienced the event is in parentheses.
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Figure 3. Two phases of eGFR changes during follow-up in the SPRINT participants with CKD. The rate of change in eGFR using the
values at 6 months after randomization as the baseline was 20.47 ml/min per 1.73 m2 per year in the intensive group (broken line and
triangles) and 20.32 ml/min per 1.73 m2 per year in the standard group (solid line and circles; P=0.03). Open symbols denote fasting
visits; closed symbols denote nonfasting visits.

eGFR observed in the intensive group was related to an acute
hemodynamic effect on the GFR. This hypothesis is supported
by our ﬁnding that the difference in the incidence of $30%
decline in eGFR between the two randomized groups disappeared after the initial 6 months of treatment. There were also
no differences in the incidence of larger ($40% or $50%)
declines in eGFR between the randomized groups during the
ﬁrst 6 months or thereafter.
The rate of decline in eGFR in both randomized groups was
low at approximately 0.5 ml/min per 1.73 m2 per year, similar
to that typically attributed to normal aging.19 Exclusion of
patients with signiﬁcant proteinuria yielded a cohort of participants in whom a relatively slow decline in kidney function was anticipated. Although the eGFR declined at a
statistically signiﬁcantly faster rate after the initial 6 months
in the intensive group compared with the standard group,
the difference was very small. In sum, these observations are
consistent with the notion that the acute lowering of SBP
to a target of ,120 mm Hg causes a modest acute hemodynamically mediated decline in GFR without further substantial deterioration thereafter during the trial. The
longer-term effects of intensive SBP lowering on kidney
function require further studies.
J Am Soc Nephrol 28: 2812–2823, 2017

The incidence of albuminuria was not signiﬁcantly different
between the randomized groups. However, the intensive group
had signiﬁcantly lower urinary ACR levels throughout the follow-up period, ﬁndings consistent with those in the AASK, in
which proteinuria decreased by 17% in the lower BP group and
increased by 7% in the standard BP group.5 This apparent
dissociation between reduction in albuminuria and lack of
improvement in clinical kidney outcomes has been seen in
previous clinical trials5,20 and suggests that albuminuria reduction may not be a suitable surrogate end point in CKD
clinical trials.
The early termination of the SPRINT intervention might
have inﬂuenced the reported outcomes in the CKD subgroup in
two ways. First, the numbers of primary CVD events, all-cause
mortality events, and primary kidney events were likely decreased. Second, the shorter duration of follow-up might have
further limited our ability to evaluate the long-term effect of the
intensive BP intervention on kidney function; this is particularly important given the acute change in eGFR in the ﬁrst few
months. Thus, long-term follow-up of the CKD subcohort
would be important.
Intensive SBP reduction was generally well tolerated by participants with CKD, although hypokalemia and hyperkalemia
Intensive BP Control in CKD
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measurement of BP, reinforcing the importance of accurate BP
measurement in clinical practice. Future practice guidelines will
likely consider the SPRINT ﬁndings along with other data to assist
clinicians in optimizing the management of hypertension in patients with CKD without diabetes.
In patients with mild to moderate CKD and hypertension
without diabetes, intensive reduction in SBP resulted in substantial reductions in CVD and all-cause death without an
effect on the incidence of $50% decline in eGFR or ESRD.
In exploratory analyses, intensive SBP lowering caused a
slightly higher rate of eGFR decline. Certain adverse events
but not overall SAEs occurred with intensive SBP treatment.
The balance of beneﬁts and harms seems to favor intensive
SBP lowering in this population.
CONCISE METHODS

Figure 4. Urinary albumin-to-creatinine ratio (UACR) in the
SPRINT participants with CKD. Geometric mean ratios of postrandomization to baseline UACR with 95% CIs. The broken line
and open circles depict the intensive treatment group; the solid
line and closed circles depict the standard treatment group. The
horizontal line at 1.0 depicts equality of means (i.e., no change in
UACR).

were more common in the intensive group, likely related
to more frequent use of medications, such as diuretics and
inhibitors of the renin-angiotensin system. ARF was also
more common in the intensive group. These complications
can potentially be prevented or managed by changing the medications or decreasing the intensity of antihypertensive therapy.
Our study has many strengths, including enrollment of the
largest number of participants with CKD and hypertension in
any randomized trial evaluating different levels of BP to date. In
addition, the study cohort was racially diverse, and a substantial
fraction of the cohort was $75 years old, allowing generalization to these important subgroups. Furthermore, the difference in SBP achieved between the two randomized groups was
substantial and maintained throughout the follow-up period.
However, progression of CKD was generally slow; hence, the
number of main kidney events was low, limiting the power of
the study to detect a treatment effect. In addition, the number
of the SPRINT participants with advanced CKD at baseline
was relatively small. As with any clinical trial, there is greater
certainty that these results are more applicable to individuals who
are similar to the SPRINT participants with regard to underlying
characteristics, such as the level of kidney function, absence of
diabetes, and relatively low levels of proteinuria. Extrapolation of
these results to other CKD subpopulations requires caution. In
addition, the SPRINT developed a standardized protocol for the
2820
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The study design and main results of the SPRINT have been reported.9,10
In brief, the SPRINT was a randomized, controlled, open label trial
conducted at 102 clinical sites sponsored by the National Heart, Lung
and Blood Institute; the National Institute of Diabetes and Digestive and
Kidney Diseases; the National Institute of Neurologic Disorders and
Stroke; and the National Institute on Aging. Major inclusion criteria
included age $50 years old, SBP of 130–180 mm Hg, and increased risk
for CVD events. CKD, deﬁned as an eGFR of 20–59 ml/min per 1.73 m2,
per se was considered a sufﬁcient criterion for increased CVD risk and
speciﬁcally targeted for recruitment. Diabetes mellitus, proteinuria .1
g/d, polycystic kidney disease, prior stroke, symptomatic heart failure,
and a left ventricular ejection fraction ,35% were major exclusion
criteria. Institutional review boards at all participating institutions approved the study protocol, and all participants provided written informed consent. The study was adherent to the Declaration of Helsinki
(trial registration: clinicatrials.gov identiﬁer NCT01206062).
Eligible participants were randomly assigned to an SBP target of
,120 mm Hg (intensive) or ,140 mm Hg (standard) at an allocation
ratio of 1:1. Antihypertensive regimens were adjusted by site investigators to achieve and maintain SBP according to their study group
assignment using published algorithms.9 Use of medications indicated for speciﬁc conditions (for example, renin-angiotensin blockers for proteinuric CKD) was encouraged. Healthy lifestyles for BP
control and CVD protection (e.g., physical activity) were recommended but not speciﬁcally monitored.
Sociodemographic data were collected at baseline. Clinical and
laboratory data were obtained at baseline and prespeciﬁed time points
thereafter in the study clinic. BP was determined using the mean of
three readings obtained with an automated machine (Model 907;
Omron Healthcare) at 1-minute intervals after the patient had been
seated quietly for 5 minutes during a study ofﬁce visit. Medical records
were obtained for documentation of events. All assays were performed
in a single central laboratory. Serum and urine creatinine values were
measured using an enzymatic procedure (Roche, Indianapolis, IN).
Urine albumin was measured using a nephelometric method (Siemens, Tarrytown, NY). The four-variable MDRD equation was used
to calculate the eGFR.21
J Am Soc Nephrol 28: 2812–2823, 2017
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Table 6. SAEs, conditions of interest, and monitored clinical events

Events

Total SAEsa
Conditions of interest
(emergency department visits or SAEs)
Hypotension
Syncope
Bradycardia
Electrolyte abnormalities
Injurious fall
ARFb
Monitored clinical events
Adverse clinical measures
Serum sodium ,130 mmol/L
Serum sodium .150 mmol/L
Serum potassium ,3.0 mmol/L
Serum potassium .5.5 mmol/L
Orthostatic hypotension
Without dizziness
With dizziness

No. of Events
(% per 1 yr)

Intensive Treatment
Versus Standard Treatment

Intensive
Treatment, n=1330

Standard
Treatment, n=1316

HR (95% CI)

P Value

627 (19.8)

640 (20.2)

0.98 (0.87 to 1.09)

0.67

51 (1.2)
54 (1.3)
37 (0.9)
69 (1.7)
125 (3.1)
114 (2.8)

38 (0.9)
42 (1.0)
40 (1.0)
51 (1.2)
138 (3.4)
78 (1.9)

1.34 (0.88 to 2.04)
1.28 (0.86 to 1.92)
0.92 (0.59 to 1.44)
1.35 (0.94 to 1.94)
0.90 (0.71 to 1.15)
1.46 (1.10 to 1.95)

0.17
0.22
0.71
0.10
0.40
0.01

49 (2.7)
3 (0.1)
30 (0.7)
106 (2.7)

35 (0.9)
0 (0)
16 (0.4)
78 (2.0)

1.39 (0.90 to 2.15)
—
1.87 (1.02 to 3.43)
1.36 (1.01 to 1.82)

0.13
.0.99
0.04
0.04

301 (8.5)
24 (0.6)

302 (8.5)
23 (0.6)

0.99 (0.85 to 1.17)
1.04 (0.59 to 1.84)

0.94
0.89

—, HR inestimable due to no events in standard treatment group.
a
SAEs were deﬁned as events that were fatal or life threatening, resulted in signiﬁcant or persistent disability, required hospitalization, or resulted in prolonged
hospitalization or medical events that the investigator judged to be a signiﬁcant hazard to the participant and required medical or surgical intervention to prevent
any of these events.
b
ARF was included as an event if the diagnosis was listed in the hospital discharge summary and considered by the SPRINT Safety Ofﬁcer, after reviewing medical
records, to be one of the top three causes for admission or continued hospitalization. A few patients with ARF were noted in the emergency department records
instead of hospitalization records.

Clinical Outcomes
A committee unaware of treatment assignment adjudicated protocolspeciﬁed clinical outcomes. The primary outcome was a composite
of nonfatal myocardial infarction, nonmyocardial infarction acute
coronary syndrome, nonfatal acute decompensated heart failure, nonfatal stroke, and death from CVD causes. Secondary outcomes
included the individual components of the primary CVD outcome,
all-cause death, and the composite of the primary CVD outcome or
all-cause death. An additional outcome was the primary CVD outcome or a cardiovascular procedure deﬁned as coronary, carotid, or
peripheral artery revascularization or partial or complete amputation
of the lower limb. Subgroup analyses for CVD outcomes in the CKD
participants, as presented in Supplemental Tables 1–3, were not
prespeciﬁed.
The main kidney outcome was a $50% decrease in eGFR from the
baseline value (conﬁrmed by repeat testing $90 days later) or development of ESRD requiring dialysis or kidney transplantation. Prespeciﬁed subgroups of interest for the main kidney outcome were
deﬁned according to sex, race, age (,75 versus $75 years old), baseline eGFR (above versus below the median), and baseline urinary
ACR (#300 versus .300 mg/g). Incident albuminuria, deﬁned as a
doubling of urinary ACR from ,10 mg/g at baseline to $10 mg/g
(conﬁrmed by repeat testing $90 days later), was another prespeciﬁed outcome. Alternative thresholds of eGFR decline ($30% and
$40%) from baseline and the rate of change in eGFR (eGFR slope)
were also examined. For analysis of the eGFR slope, we separately
J Am Soc Nephrol 28: 2812–2823, 2017

examined the entire follow-up period and the follow-up period starting at 6 months after randomization, anticipating an acute decline in
eGFR with intensive SBP lowering as seen in previous trials.5
Included in this analysis are all events that occurred on or before
August 20, 2015, although some eGFR or albuminuria events were
conﬁrmed by measurements in samples collected after that date. All
data for this analysis were locked on January 31, 2016 instead of
October 14, 2015 for the report of the primary results.10 This change
in date resulted in four and ﬁve additional primary CVD events in the
intense and standard groups, respectively, as well as one and one
additional main composite kidney events in the intensive and standard groups, respectively. It has not fundamentally changed interpretation of the results.

SAEs and Adverse Events of Special Interest
Adverse events, including SAEs, were monitored as previously described.9,10 Several conditions not classiﬁed as SAEs were felt to be
of particular interest for SBP interventions and speciﬁcally monitored if they were evaluated in an emergency department; these included hypotension, syncope, bradycardia, electrolyte abnormalities,
injurious falls, and ARF. In addition, adverse laboratory measures and
orthostatic hypotension were prespeciﬁed events to be monitored.
Orthostatic hypotension was deﬁned as a decrease in SBP of $20 mm
Hg or a decrease in DBP of $10 mm Hg at 1 minute after transitioning from the sitting to the standing position. Participants were asked
if they felt dizzy at that time.
Intensive BP Control in CKD
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Statistical Analyses
Mean SBP during follow-up was compared between the two treatment
groups using mixed linear models with unstructured variance-covariance
to control for within-subject correlation. Time to the ﬁrst event was
compared between the two treatment groups on the basis of the intention
to treat approach using Cox proportional hazards regression models with
two-sided tests at the 5% level of signiﬁcance and stratiﬁcation by
clinical site. Follow-up was censored at the date of last assessment for a
study event in each participant before August 21, 2015. Two-way
interactions between treatment effect and baseline CKD status
were assessed using likelihood ratio tests and the Hommel technique
to adjust for multiple comparisons.22 Numbers needed to treat for
beneﬁt or harm at 4 years of follow-up and the 95% CIs were calculated as the inverses of the absolute risk reductions and the inverses
of the absolute risk increases, respectively, using 4-year Kaplan–
Meier survival estimates.23,24
There was a systematic difference in serum creatinine concentrations between blood samples obtained at fasting (baseline and 12, 24,
and 48 months) and nonfasting (all other time points) visits. The mean
eGFR was 0.9 ml/min per 1.73 m2 (1.9%) lower in the fasting compared with the nonfasting samples. An independent mixed effects
linear model, with an unstructured variance-covariance matrix, was
used to estimate annualized eGFR slopes for the period starting at 6
months after randomization (“chronic slope”).
All analyses were performed using (SAS version 9.4 software; SAS
Institute Inc., Cary, NC).
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SUPPLEMENTAL MATERIALS

1

Supplemental Figure 1. CONSORT Diagram of Eligibility, Randomization, and Follow-up for the entire
Systolic Blood Pressure Intervention Trial (SPRINT) Cohort.

Screened
N=14,692

Eligible
N=10,261

Total ineligible: N=4,091
Age <50: N=34
Low standing BP: N=352
BP/meds: N=2,284
Not high risk: N=718
Miscellaneous: N=703

Randomized
N=9,361

CKD Subgroup
N=2,646

Intensive BP
N=1,330

Standard BP
N=1,316

Discontinued intervention: N=68
Lost to follow-up: N=22
Withdrawn consent: N=45

Discontinued intervention: N=97
Lost to follow-up: N=37
Withdrawn consent: N=28

Analyzed: N=1,330
Excluded: N=0

Analyzed: N=1,316
Excluded: N=0

2

Supplemental Table 1. Incidence of Primary Cardiovascular Outcome Stratified by Baseline Characteristics in SPRINT Participants with Chronic
Kidney Disease.

Intensive Treatment
Intensive Treatment

Baseline
Characteristics
Age

Gender

Race

Subgroup by
Baseline
Characteristics
N

Albuminuria

vs. Standard Treatment

N

No.
Events

% per
Yr.

Hazard ratio (95% CI)

P-value

746

55

2.27

739

47

1.93

1.11 (0.74-1.66)

0.63

≥75 years

584

57

3.24

577

84

5.05

0.64 (0.45-0.92)

0.01

Female

537

35

1.98

521

43

2.60

0.62 (0.39-0.99)

0.05

Male

793

77

3.19

795

88

3.59

0.87 (0.64-1.20)

0.40

Black

328

29

2.80

316

26

2.61

1.02 (0.58-1.81)

0.94

1002

83

2.64

1000

105

3.38

0.77 (0.57-1.03)

0.08

eGFR ≤ median

660

72

3.53

664

81

3.98

0.91 (0.65-1.27)

0.58

eGFR > median

670

40

1.87

652

50

2.42

0.78 (0.50-1.20)

0.26

ACR ≤ median

671

34

1.56

637

37

1.80

0.84 (0.51-1.36)

0.48

ACR > median

647

77

3.91

661

92

4.59

0.81 (0.59-1.11)

0.20

*P-value adjusted for multiple comparisons
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Treatment × Baseline
Characteristics
Interaction
Adjusted

% per
Yr.

<75 years

Non-black
Kidney function

No.
Events

Standard Treatment

P-value

P-value*

0.04

0.18

0.31

0.70

0.34

0.70

0.47

0.86

0.86

0.86

Supplemental Table 2. All-Cause Mortality Stratified by Baseline Characteristics in SPRINT Participants with Chronic Kidney Disease.

Intensive Treatment
Intensive Treatment

Baseline
Characteristics
Age

Gender

Race

Subgroup by
Baseline
Characteristics
N

Albuminuria

vs. Standard Treatment

N

No.
Events

% per
Yr.

Hazard ratio (95% CI)

P-value

746

26

1.04

739

31

1.24

0.84 (0.49-1.44)

0.52

≥75 years

584

44

2.38

577

64

3.57

0.64 (0.43-0.96)

0.03

Female

537

24

1.32

521

28

1.62

0.73 (0.41-1.31)

0.30

Male

793

46

1.81

795

67

2.60

0.71 (0.48-1.03)

0.07

Black

328

19

1.77

316

15

1.26

1.26 (0.60-2.68)

0.54

1002

51

1.55

1000

80

2.45

0.63 (0.44-0.90)

0.01

eGFR ≤ median

660

49

2.29

664

62

2.88

0.82 (0.56-1.21)

0.32

eGFR > median

670

21

0.95

652

33

0.62

0.62 (0.34-1.10)

0.10

ACR ≤ median

671

23

1.03

637

24

1.13

0.98 (0.54-1.77)

0.94

ACR > median

647

47

2.26

661

70

3.29

0.66 (0.45-0.97)

0.03

*P-value adjusted for multiple comparisons
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Treatment × Baseline
Characteristics
Interaction
Adjusted

% per
Yr.

<75 years

Non-black
Kidney function

No.
Events

Standard Treatment

P-value

P-value*

0.54

0.79

0.79

0.79

0.12

0.50

0.39

0.79

0.20

0.79

Supplemental Table 3. Incidence of Composite of Primary Cardiovascular Outcomes and All-Cause Death Stratified by Baseline Characteristics
in SPRINT Participants with Chronic Kidney Disease.

Intensive Treatment
Intensive Treatment

Baseline
Characteristics
Age

Gender

Race

Subgroup by
Baseline
Characteristics
N

Albuminuria

% per
Yr.

vs. Standard Treatment

N

% per
Yr.

Hazard ratio (95% CI)

P-value

746

71

2.92

739

64

2.62

1.09 (0.77-1.54)

0.64

≥75 years

584

81

4.58

577

115

6.88

0.66 (0.49-0.90)

0.01

Female

537

48

2.71

521

59

3.57

0.64 (0.43-0.96)

0.03

Male

793

104

4.29

795

120

4.87

0.89 (0.68-1.16)

0.40

Black

328

38

3.66

316

34

3.41

1.00 (0.61-1.64)

0.98

1002

114

3.61

1000

145

4.65

0.78 (0.61-1.01)

0.06

eGFR ≤ median

660

98

4.78

664

113

5.52

0.89 (0.67-1.18)

0.40

eGFR > median

670

54

2.51

652

66

3.19

0.79 (0.54-1.16)

0.23

ACR ≤ median

671

50

2.29

637

52

2.52

0.88 (0.59-1.32)

0.54

ACR > median

647

101

5.11

661

124

6.17

0.83 (0.63-1.09)

0.18

*P-value adjusted for multiple comparison
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Treatment × Baseline
Characteristics
Interaction
Adjusted

No.
Events

<75 years

Non-black
Kidney function

No.
Events

Standard Treatment

P-value

P-value*

0.04

0.21

0.28

0.61

0.32

0.61

0.50

0.61

0.61

0.61

Supplement Table 4. Serious Adverse Events, Conditions of Interest, and Monitored Clinical Events
During the Entire Follow-up Period.

Events
b
Total serious adverse events

Intensive
Treatment

Standard
Treatment

(N=1330)
a
No. (%)

(N=1316)
a
No. (%)

627 (47.1)

640 (48.6)

Intensive Treatment
vs. Standard Treatment
Hazard ratio
(95% CI)
0.98 (0.87-1.09)

Conditions of interest (emergency department visits or serious adverse events)
Hypotension
51 (3.8)
38 (2.9)
1.34 (0.88-2.04)
Syncope
54 (4.1)
42 (3.2)
1.28 (0.86-1.92)
Bradycardia
37 (2.8)
40 (3.0)
0.92 (0.59-1.44)
Electrolyte abnormalities
69 (5.2)
51 (3.9)
1.35 (0.94-1.94)
Injurious fall
125 (9.4)
138 (10.5)
0.90 (0.71-1.15)
c
Acute renal failure
114 (8.6)
78 (5.9)
1.46 (1.10-1.95)
Monitored clinical events
Adverse clinical measures
Serum sodium <130 mmol/l
Serum sodium >150 mmol/l
Serum potassium <3.0 mmol/l
Serum potassium >5.5 mmol/l
Orthostatic hypotension
Without dizziness
With dizziness

P value
0.67

0.17
0.22
0.71
0.10
0.40
0.01

49 (3.7)
3 (0.2)
30 (2.3)
106 (8.0)

35 (2.7)
0 (0)
16 (1.2)
78 (5.9)

1.39 (0.90-2.15)
1.87 (1.02-3.43)
1.36 (1.01-1.82)

0.13
1.00
0.04
0.04

301 (22.6)
24 (1.8)

302 (22.9)
23 (1.7)

0.99 (0.85-1.17)
1.04 (0.59-1.84)

0.94
0.89

a

Total number of events and percentage of the cohort with those events over the entire duration of follow-

up of 3.3. years.
b

Serious adverse events were defined as events that were fatal or life-threatening, resulted in

significant or persistent disability, required hospitalization or resulted in prolonged hospitalization, or
medical events that the investigator judged to be a significant hazard to the participant and required
medical or surgical intervention to prevent any of these.
c

Acute renal failure was included as an event if the diagnosis was listed in the hospital discharge

summary and was considered by the SPRINT Safety Officer, after reviewing medical records, to be one
of the top three causes for admission or continued hospitalization. A few cases of acute renal failure
were noted in the emergency-department records instead of hospitalization records.

6

Supplemental Table 5. Number needed to treat for benefit (NNTB) or harm (NNTH) at four years
follow-up for selected outcomes and adverse events.

Outcomes
Primary (CVD) outcome
CVD death
All-cause death
Primary outcome or all-cause death
Adverse events
Acute renal failure
Serum potassium <3.0 mmol/L
Serum potassium >5.5 mmol/L

NNTB/NNTH

95% CIa

NNTB 66
NNTB 61
NNTB 28
NNTB 37

NNTB 22 to ∞ to NNTH 66
NNTB 32 to ∞ to NNTH 544
NNTB 16 to 90
NNTB 16 to ∞ to NNTH 151

NNTH 35
NNTH 131
NNTH 41

NNTH 18 to 1239
NNTH 43 to ∞ NNTB 124
NNTH 21 to 14626

95% CI was calculated as previously described.23,24

a
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